Ligand Pharmaceuticals Incorporated
LGND evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LGND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LGND
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial medicines, generating non-dilutive cash flows with a lean cost structure.
Key risk: Partner dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$5.59B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial medicines, generating non-dilutive cash flows with a lean cost structure.
- Ligand's primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products [sec · filed 2026-04-21].
- As of 2026-06-30, the company reported cash & equivalents of $1,006.7M, total revenue of $63.7M, net income of $48.5M, shareholders' equity of $1,017.2M, and total debt of $1,126.6M [sec].
- In 2025, Ligand invested $131 million and added 10 new programs to its portfolio through spin-offs, asset purchases, and other investments [sec · filed 2026-04-21].
- The company relies on collaborative partners for milestone payments, royalties, materials revenue, and other contract payments [sec · filed 2026-04-27].
- Ligand's portfolio includes nine major royalty revenue contributors such as Kyprolis, Rylaze, Filspari, Qarziba, and others [sec · filed 2025-04-22].
What works
- Ligand's business model generates long-duration, non-dilutive cash flows supported by a lean corporate cost structure, avoiding high-cost infrastructure by leveraging partners' capabilities [sec · filed 2026-04-21].
- The company has a disciplined investment process with proprietary origination and deep industry relationships, allowing it to evaluate opportunities earlier and structure transactions with precision [sec · filed 2026-04-21].
- Ligand's portfolio is diversified across multiple therapeutic areas and products, which mitigates the high volatility associated with single-asset biotech companies [sec · filed 2024-04-25].
What to weigh
- Ligand relies on collaborative partners for milestone payments, royalties, and other revenue projections, exposing it to risks associated with partners' commercial success and drug development outcomes [sec · filed 2026-04-27].
- The company faces uncertainties inherent in business and financial planning, including adverse developments in capital markets, regulatory environments, tariffs, and trade policies [sec · filed 2026-04-27].
- As of 2026-06-30, Ligand had total debt of $1,126.6M against shareholders' equity of $1,017.2M, indicating a leveraged balance sheet [sec].
From the filings
Quoted directly from source documents.
Ligand's primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products.
“Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.”
SEC filings · April 21, 2026
Ligand relies on collaborative partners for milestone payments, royalties, and other revenue.
“XOMA Royalty's and Ligand's reliance on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections”
SEC filings · April 27, 2026
Ligand's business model mitigates the high volatility associated with single-asset biotech companies.
“our business model mitigates the high volatility associated with building a business around a single or small number of assets”
SEC filings · April 25, 2024
Ligand added 10 new programs to its portfolio in 2025.
“Added 10 new programs through spin-off, assets purchase and other investments”
SEC filings · April 21, 2026
Risks & what to watch (3)›
Key risks
- Partner dependency — Ligand relies on collaborative partners for milestone payments, royalties, and revenue, exposing it to partners' commercial and development risks [sec · filed 2026-04-27].
- Market and regulatory uncertainty — Adverse developments in capital markets, regulatory environments, tariffs, and trade policies could impact Ligand's business [sec · filed 2026-04-27].
- High leverage — As of 2026-06-30, total debt of $1,126.6M exceeds shareholders' equity of $1,017.2M, indicating a leveraged balance sheet [sec].
What to watch
- Progress of newly added programs from the 2025 investment of $131 million and their path to potential royalty revenue between 2028 and 2030 [sec · filed 2026-04-21].
- Commercial uptake of recently approved portfolio products such as Ohtuvayre, Filspari, and Capvaxive [sec · filed 2025-04-22].
- Ligand's ability to continue generating royalty revenue growth and core cash flow while managing its debt obligations [sec].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run Ligand Pharmaceuticals Incorporated through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ligand Pharmaceuticals Incorporated facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.26 · 9% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 87 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
353
Total value held
$4.19B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,961,923 | $591.3M |
| janus henderson group plc | 2,019,782 | $403.2M |
| vanguard capital management llc | 1,696,178 | $338.6M |
| vanguard portfolio management llc | 1,100,267 | $219.7M |
| state street corp | 778,856 | $155.5M |
| fmr llc | 596,127 | $119.0M |
| nomura asset management international inc. | 573,312 | $114.5M |
| franklin resources inc | 573,177 | $114.4M |
| geode capital management, llc | 558,934 | $111.6M |
| congress asset management co | 504,637 | $100.8M |
Showing top 10 of 353 institutional holders of Ligand Pharmaceuticals Incorporated. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.7%
- Days to cover
- 6.5
- Shares short
- 1,455,087
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LGND short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial medicines, generating non-dilutive cash flows with a lean cost structure.
Who is the CEO of Ligand Pharmaceuticals Incorporated?
Mr. Todd C. Davis Ph.D. is the chief executive officer of Ligand Pharmaceuticals Incorporated (LGND).
Where is Ligand Pharmaceuticals Incorporated headquartered?
Ligand Pharmaceuticals Incorporated (LGND) is headquartered in Jupiter, FL, United States.
What therapeutic areas does Ligand Pharmaceuticals Incorporated focus on?
Ligand Pharmaceuticals Incorporated develops therapies across Neurology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.